@article{article_268787, title={PULMONARY RESECTIONS AFTER NEOADJUVANT THERAPY IN PATIENTS WITH PRIMARY LUNG CARCINOMA: RE-EVALUATION OF THE FIRST 90 PATIENTS WITH RECENT EXPERIENCE}, journal={Journal of Istanbul Faculty of Medicine}, volume={79}, pages={1–8}, year={2016}, DOI={10.18017/iuitfd.60951}, author={Özkan, Berker and Kaba, Erkan and Erus, Suat and Kapdağlı, Murat and Ziyade, Sedat and Tanju, Serhan and Demir, Adalet and Dilege, Şükrü and Toker, Alper}, keywords={Lung cancer,thoracic surgery,surgery after neoadjuvant treatment}, abstract={<p class="MsoNormal" style="text-align:justify;"> <b> <span style="font-size:10pt;">Objective: </span> </b> <span style="font-size:10pt;">In this study, we aimed to analyse the non-small cell
lung carcinoma patients who have undergone surgery after neoadjuvant
chemo/chemoradiotherapy <b> </b>in regards
to recurrences, survival, complication, morbidity, and mortality. </span> </p> <p> </p> <p class="MsoNormal" style="text-align:justify;"> <b> <span style="font-size:10pt;">Materials and Methods: </span> </b> <span style="font-size:10pt;">The data of 90 patients who had surgeries between June
2001 and December 2008 were retropectively evaluated. Fifty nine of those 90
patients had neoadjuvant chemotherapy and 31 patients had neoadjuvant
chemoradiotherapy. Patients were divided into 3 groups; 47 patients were
clinical T3/N2, 23 patients were clinical T4(N0-1), 20 patients were
histopatologically proven N2(T1-3). Age, gender, tumor pathology, resection
type, complications, mortality and survival rates of the patients were
evaluated. </span> </p> <p> </p> <p class="MsoNormal" style="text-align:justify;"> <b> <span style="font-size:10pt;">Results: </span> </b> <span style="font-size:10pt;">There were 76 male, 14 female patients in our study
group. Mean age was 55.3±8.5 (36-75) years. Thirty six patients had lobectomy,
11 patients had extended resections with lobectomy, 13 patients had sleeve
lobectomy, and 30 patients had pneumonectomy operations. Major complication and
mortality rates were 14.4% and 2.2% respectively. Minimal and mean follow-up
periods were 24 and 27±18 months
respectively. Mean survival was calculated as 25±4.6 months (pathological stage
I: 35±9.7 months, stage II: 33±8.5 months, stage IIIa: 24±9.7 months, and stage
IIIb: 14±10.9 months). Mean survival was 26±6.7 months in clinical T3/N2 group,
14±2.2 months in T4 group, 41±3.7 months in histopathological N2 group. There
was a statisticaly significant difference in survival times between clinical
T3/N2 and histopathological N2 groups ( <i>p </i><0.05). </span> </p> <p> </p> <p class="MsoNormal" style="text-align:justify;"> <b> <span style="font-size:10pt;">Conclusion: </span> </b> <span style="font-size:10pt;">Lung resections after neoadjuvant therapy can be
achieved with acceptable rates of complications, morbidity, and mortality.
Surgery in selected patients with proper mediastinal staging may also provide
longer survival. </span> </p>}, number={1}, publisher={Istanbul University}